Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction
Andrew R. Kompa(The University of Melbourne), Henry Krum(Australian Regenerative Medicine Institute), Bing H. Wang(Monash University), Stephen Eisennagel(Pathways Behavioral Services), David J. Behm(GlaxoSmithKline (United States)), Darren J. Kelly(ETH Zurich), Yuan Zhang, Guoying Xu(Shaoxing People's Hospital), Reema K. Thalji(Pathways Behavioral Services), Joseph P. Marino(Pathways Behavioral Services), Pei-Yu Ho(Monash University)
Cited by 43
Related Papers
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
|European Journal of Heart Failure|2012|1.1k